Neuronetics, Inc. is thrilled to announce a significant milestone with a successful funding round that secured $50,000,000, a testament to our shared commitment to mental health innovation. As the creator of NeuroStar Advanced Therapy—the market leader in Transcranial Magnetic Stimulation (TMS) for the treatment of Major Depressive Disorder and various other mental health conditions—this capital infusion will serve as a catalyst for evolving our mission to transform patient care on a global scale. Based in Malvern, PA, and operating as a public medical device company under the ticker STIM, Neuronetics harnesses decades of expertise to deliver breakthrough neurohealth therapies that address mental health care in its very origin: the brain.
With more than 6.4 million treatments already performed to date, NeuroStar remains the first choice for physicians seeking a non-pharmaceutical, non-invasive alternative to conventional treatments like shock therapy or surgery. Each outpatient session, lasting as little as 20 minutes over a series of 36 sessions, is designed to promote neuroplasticity and target mental health at its source. Thanks to this new funding, we are poised to accelerate research and development, expand our global footprint, and further refine our innovative therapy options. This strategic investment will also enhance our ability to provide comprehensive patient education and support, ensuring that everyone in need of mental health care can access our state-of-the-art technology. We are grateful for the continued confidence from our investors and committed to saving lives and advancing mental health care with every NeuroStar treatment. For more details or inquiries, please reach out via customersupport@neurostar.com or call (877) 600-7555.
